Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are you 10 years old? Have some patience. I actually think this pullback is the right time to add to my position. JMO
Getting some positive price movement yesterday and today.
As am I still long. Starting to get annoyed. No reason to curse. Up till Diddo showing up, I was very happy with all the posters and their opinions, information and posts. Let's keep it positive.
Although CDXC's PPS has gone down more than I thought, the company is performing well, as we hopefully will find out through next Thursdays report. If the report is positive, as I believe it will be I will add to my position at these extremely low prices. Niagen, is a once in a lifetime product, and CDXC owns it. JMO
Great post 'someconcerns'. I also think that long term CDXC is going to be a huge winner. Patience is needed but will pay off.
ChromaDex Appoints Kurt Gustafson to its Board of Directors
IRVINE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Kurt Gustafson has joined the Company’s board of directors. Mr. Gustafson will also serve as chair of ChromaDex’s audit committee.
Mr. Gustafson, age 48, has more than 25 years of diverse experience in corporate finance. He currently serves as chief financial officer, principal accounting officer and executive vice president of Spectrum Pharmaceuticals, Inc. He previously served as the chief financial officer of Halozyme Therapeutics, Inc.(2009 – 2013). From 1991 to 2009 he worked at Amgen, holding various financial roles as vice president finance, chief financial officer of Amgen International and treasurer. Prior to joining Amgen, he worked in public accounting as staff auditor at Laventhol & Horwath in Chicago. He has been an independent director of Xencor, Inc. since 2014. Mr. Gustafson holds a B.A. degree in Accounting from North Park University in Chicago and an M.B.A from University of California, Los Angeles.
Diddo...it is depressing to see CDXC's PPS perform so badly. I had high hopes at the start oft this year that we would see high single digits before this year ended but now i can see that it is going to be next year before that is going to happen. The company needs to keep performing as it has so far this year and the PPS will overcome it's short term performance. JMO
Leading Supplement Retailer Features NIAGEN® as Their Hot Ingredient for Fall, 2016
NR and NAD+ gaining more attention as consumers continue to look for ways to rejuvenate their energy
IRVINE, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced leading supplement retailer, Vitamin Shoppe, featured NIAGEN® nicotinamide riboside (NR) in their Hot Ingredient Spotlight section in the Fall 2016 print edition of their Amazing Wellness magazine.
ChromaDex founder and CEO, Frank Jaksch, Jr. commented, “As the aging population continues to grow, their interest in what can be done to rediscover that sense of vitality or youthful energy grows. The scientific evidence validating NR’s ability to increase cellular NAD+, has people interested and wanting to learn more.” Jaksch continued, “This type of coverage is a perfect complement to the ongoing consumer outreach we are doing to help people understand that the answer lies within their own cells.”
I would not be surprised if this is FROST dumping again.
I'm starting to realy hate Seeking Alpha...
seekingalpha.com/article/4006523-getting-cautious-chromadex-potential-channel-stuffing
My thoughts are, I wish I knew if this was a one time event or if he is going to continue selling until he is out. Frost has a ton of shares and could keep the PPS down for a long time unless CDXC gets some institutions to take out his position. I wish I knew his reasons for selling. we shall have to wait and see unless someone else on this board has some knowledge about Frosts reasoning.
Since July 27, 2016 (and up to and including September 12, 2016), the Reporting Person (Phillip Frost) has sold 414,500 shares of the Issuer’s common stock at prices ranging from $3.16 to $4.40 on the open market.
Well....That explains a lot. I wonder what he has in store for us going forward.
ChromaDex to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
The presentation at this conference is extremely important. I had stated before that we are in buyers strike. If we start to get institutions buying after the conference. we will see the PPS start to move up and gain some momentum. We have gained some good institutional buying in the recent past. I am hoping that the PPS being as cheap as it is today for a potential huge growth stock will entice them to start buying. JMO
It appears to me that we are in a buyers strike. Very little volume and I can't figure out why after an excellent report. Maybe going to the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016 we'll start to get some buying.
Quote from transcript...
ChromaDex was added to the Russell 2000, the Russell 3000, the Russell Microcap and the Russell Global Indices. As a result of being added to the Russell 2000 index, we have seen an increase in institutional ownership. The new NASDAQ listing and being added to several Russell indices has dramatically changed our institutional ownership, a trend we expect to continue during 2016. We expect analyst coverage in the very near term and we will continue to actively pursue additional analyst coverage in 2016.
It can't happen fast enough.
Sorry about that. Go to yahoo site and search CDXC. You will find the transcript under the summary info.
Edited Transcript of CDXC earnings conference call or presentation 11-Aug-16 8:30pm GMT.....
[/url][tag]http://finance.yahoo.com/news/edited-transcript-cdxc-earnings-conference-171621456.html[/tag]
ETF's with exposure to CDXC.
http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-chromadex-corp-august-19-2016/
Click on text and you will see how many new purchases have been made by institutions. My feeling is that this is just the beginning. Where will the PPS when institutions own 40% of the shares and our sales are going through the roof. JMO
Institutional Ownership 09.39%
insert-text-here
My thoughts are that all those who bought at the bottom when CDXC was shorted, are going to take profits as the PPS increases. It will take some time to work through all the nonsense that took place. Unfortunately for us long term holders, our time span has been pushed out.
Bollinger bands starting to expand right before earnings tells me we should have a nice move coming as volatility increases. Hopefully one that carries us back to the $5/6 range.
I see the biggest detriment to our PPS going up quickly and substantially are all the flippers that were produced from the article having driven the price so far down. I am sure all those that profited from shorting CDXC were also buyers at those low, bargain prices and then knowing of the articles retraction, bought even more shares. I don't think they are long term shareholders so every two steps forward will be met with one step backward. I hope I am wrong. One caviat, would be a fantastic earnings report. One beyond all our expectations. That might drive institutions into large purchases, driving the PPS much higher. JMO
Not sure what you mean 4ever...Do you mean increased sales are likely to be reported but lower earnings or profits? Not sure what would cause that.
Bolinger Bands starting to get real tight which indicates very low volatility and would indicate a large move up or down in the near future. They can get tighter before they breakout like until our next earnings report.
These institutional purchases do not surprise me since we were listed in the Russell 2000 index.
Unfortunately, It appears that we are going to have to wait for the nextquraterly report in order to gain back what we have lost. I was hoping that the company would come out with an interim PR that would indicate how sales and profits were doing but that does not seem to be in the cards. $6 has now been pushed out for a while. CDXC technicals were really hurt by the recent nonsence. JMO
Would anyone consider being an assistant moderator.
I became the Moderator because I was trying to get more involvement by people owning CDXC shares and unfortunately it took a negative article to really get the board more active. As moderator, I can only sticky ONE post. It would help to have another moderator or two so that more posts can be stickied in the future plus the board will get more new ideas. Please consider it. Have a great July Fourth weekend. Thanks, Pat
I very happy to see new posters on the board. For those posters who are scientifically oriented and interested in more info about NR I present this web site. It's way over my head but....
insert-text-here
The url starts at page 30 but you probably should start at page 1.
If I remember correctly, Jockish said that he and other CDXC employees take 250 everyday.
It really Po's me. We would be going through $6 right now after being added to the Russell 2000 if it were not for the article. CDXC should still sue Bleeker street for any reason they can come up with. JMO
Golllly. Do you think they will return all the money they made.
We need to break through $3.30 and I think we will start heading back up to the $5.00 range. JMO
I hope that CDXC being added to small cap index's will add some new buyers and start raising the PPS where it should be.
ChromaDex Added to the Russell 2000® Index
IRVINE, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a leading provider of proprietary science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today announced that the company has been added to the Russell 2000®, the Russell 3000®, the Russell Microcap® Index and the Russell Global Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opened on June 27, according to a final list of additions posted June 27, 2016.
Frank Jaksch Jr., Founder and CEO of ChromaDex, commented, “Joining the Russell 2000® Index allows us further visibility within the investment and analyst community, above and beyond what was generated by our uplisting to NASDAQ just last month.”
Annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of the end of May, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes by objective, market-capitalization rankings and style attributes.
Indexes provided by FTSE Russell, a leading global index provider, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $6 trillion in assets are benchmarked against the Russell US indexes.
For more information on the Russell 3000® Index and the Russell US Indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
Great post and article Karin. Thanks
Positive article about
www.nutraingredients-usa.com/Markets/ChromaDex-stock-slide-caused-by-baseless-allegations-CEO-says
ChromaDex Responds to Short Attack
IRVINE, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans to respond to a report published today by an anonymous party on a stock-discussions website.
Frank L. Jaksch, Founder and CEO, ChromaDex, stated, "The report appears to be a blatant and transparent attempt by a shortseller or shortsellers to profit from an immediate and precipitous decline in the company's share price through the use of an opinion piece published anonymously and laden with misinformation, innuendo and the use of selective historical information. It is also important for investors in ChromaDex and other stakeholders to carefully consider the statement the author made on the last page of his/her editorial attacking the company: 'I am/we are short CDXC. I wrote this article myself, and it expresses my own opinions.'"
Jaksch continued, "ChromaDex is exploring its options in response to this attack."
I don't see any problem regarding P&G. I owned shares in another company that had a deal with a large drug company and everything was a secret and could be made public.